Palisade Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.71M Buy
9,475
+8,250
+673% +$8.36M 0.29% 106
2025
Q4
$1.32M Buy
1,225
+556
+83% +$532K 0.04% 272
2025
Q3
$511K Buy
669
+278
+71% +$207K 0.01% 339
2025
Q2
$305K Buy
391
+71
+22% +$55.2K 0.01% 353
2025
Q1
$264K Hold
320
0.01% 364
2024
Q4
$247K Hold
320
0.01% 355
2024
Q3
$284K Buy
+320
New +$288K 0.01% 349
2024
Q1
Sell
-745
Closed -$434K 368
2023
Q4
$434K Hold
745
0.01% 348
2023
Q3
$400K Hold
745
0.01% 340
2023
Q2
$349K Hold
745
0.01% 340
2023
Q1
$256K Hold
745
0.01% 369
2022
Q4
$273K Hold
745
0.01% 378
2022
Q3
$241K Hold
745
0.01% 389
2022
Q2
$242K Hold
745
0.01% 406
2022
Q1
$213K Sell
745
-255
-26% -$65.6K ﹤0.01% 411
2021
Q4
$276K Buy
+1,000
New +$254K 0.01% 401

Other funds holding LLY

Palisade Capital Management's LLY Position: Q1 2026 in Review

Palisade Capital Management increased its Eli Lilly (LLY) stake by 673% in Q1 2026, buying an estimated $8.36M and bringing the position to 9,475 shares worth $8.71M. The position accounts for 0.29% of the portfolio, ranked #106.

Palisade Capital Management first reported a position in LLY in Q4 2021 and has held it in 16 quarters since. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Palisade Capital Management held 9,475 shares of Eli Lilly worth $8.71M as of Q1 2026.
  • Palisade Capital Management bought 8,250 Eli Lilly shares in Q1 2026, an estimated $8.36M.
  • Eli Lilly made up 0.29% of Palisade Capital Management's portfolio in Q1 2026, its #106 holding.
  • Palisade Capital Management first reported a position in Eli Lilly in Q4 2021 and has held it in 16 quarters since.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Palisade Capital Management's 13F filing for Q1 2026, filed 15 May 2026.